Mouse Anti-VEGFA Recombinant Antibody (clone AB014) (CAT#: HPAB-0715-FY)

Figure 1 ABT-165 DVD-Ig inhibits the function of DLL4 and VEGF.

VEGF potentiates the activity of ABT-165. The activities of ABT-165 and the combination of DLL4 and VEGF mAb mixture were analyzed in the Notch activation bioassay in the presence or absence of recombinant VEGF (6 nmol/L). A nonrelevant recombinant protein, BSG2, was used as the negative control.

Li, Y., Hickson, J. A., Ambrosi, D. J., Haasch, D. L., Foster-Duke, K. D., Eaton, L. J., ... & Zhang, C. (2018). ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting DLL4 and VEGF, demonstrates superior efficacy and favorable safety profiles in preclinical models. Molecular cancer therapeutics, 17(5), 1039-1050.

Figure 2 ABT-165 inhibits tumor growth and decreases functional tumor angiogenesis.

U87-MG xenograft tumors were sectioned seven days postintraperitoneal administration of a single 5 mg/kg dose of mAbs or 6.7 mg/kg dose of ABT-165. Within viable regions of treated tumors, lectin perfusion (FITC, green) or anti-CD31 (PE, red) staining was performed. Colocalization for both lectin/FITC and CD31/PE labeling is depicted in orange (Merge panel). Nuclei were stained with DAPI (blue). Percent positive functional vessels (lectin staining), and vascular density quantitation (CD31 staining) are graphed below (*, P values <0.05 compared with control group).

Li, Y., Hickson, J. A., Ambrosi, D. J., Haasch, D. L., Foster-Duke, K. D., Eaton, L. J., ... & Zhang, C. (2018). ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting DLL4 and VEGF, demonstrates superior efficacy and favorable safety profiles in preclinical models. Molecular cancer therapeutics, 17(5), 1039-1050.